



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

U.S. Patent and Trademark Office  
Box SEQUENCE  
P.O. Box 2327  
Arlington, VA 22202

On Dec. 5, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Patricia Anders

**PATENT**  
Attorney Docket No.: 015280-356100US  
Client Ref. No.: E-201-98/2

#11/B  
JRW  
12/18/02

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

PASTAN *et al.*

Application No.: 09/673,707

Filed: January 11, 2001

For: RECOMBINANT IMMUNOTOXIN  
DIRECTED AGAINST THE HIV-1  
GP120 ENVELOPE GLYCOPROTEIN

Examiner: Zeman, Robert A.

Art Unit: 1645

**COMMUNICATION UNDER**

**37 C.F.R. §§ 1.821-1.825**

**AND**

**AMENDMENT**

**RECEIVED**

DEC 18 2002

TECH CENTER 1600/2000

U.S. Patent and Trademark Office  
Box SEQUENCE  
P.O. Box 2327  
Arlington, VA 22202

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed November 5, 2002, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Applicants also take this opportunity to correct some typographical errors noted in the course of preparing the Sequence Listing.

In accordance with 37 C.F.R. §§ 1.821-1.825, please amend the specification as follows.